This PDF is the current document as it appeared on Public Inspection on 10/14/2016 at 08:45 am.
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:
Time and Date: 9:00 a.m.-5:00 p.m., November 3, 2016 (All times are Eastern Daylight Time).
Place: Jacob J. Javits Federal Building, 26 Federal Plaza, New York, New York 10278. This meeting is also available by telephone and Web conference. Audio will be available by telephone only; visuals will be available by Web conference. The USA toll-free, dial-in number is 1-888-810-4931, and when prompted enter passcode—8328289. To view the web conference, enter the following web address in your web browser: https://odniosh.adobeconnect.com/wtchpstac/.
Public Comment Time and Date: 10:45 a.m.-11:15 a.m. (Eastern Daylight Time), November 3, 2016.
Please note that the public comment period ends at the time indicated above or following the last call for comments, whichever is earlier. Members of the public who want to comment must sign up by providing their name by mail, email, or telephone, at the addresses provided below by October 31, 2016. Each commenter will be provided up to five minutes for comment. A limited number of time slots are available and will be assigned on a first come—first served basis. Written comments will also be accepted from those unable to attend the public session.
Status: Open to the public, limited only by the number of telephone lines. The conference line will accommodate up to 50 callers. The room will accommodate approximately 100 persons.
Background: The Advisory Committee was established by Title I of the James Zadroga 9/11 Health and Compensation Act of 2010, Public Law 111-347 (January 2, 2011), amended by Public Law 114-113 (Dec. 18, 2015), adding Title XXXIII to the Public Health Service Act (codified at 42 U.S.C. 300mm to 300mm-61).
Purpose: The purpose of the Advisory Committee is to review scientific and medical evidence and to make recommendations to the World Trade Center (WTC) Program Administrator regarding additional WTC Health Program eligibility criteria, potential additions to the list of covered WTC-related health conditions, and research regarding certain health conditions related to the September 11, 2001 terrorist attacks.
Title XXXIII of the PHS Act established the WTC Health Program within the Department of Health and Human Services (HHS). The WTC Health Program provides medical monitoring and treatment benefits to eligible firefighters and related personnel, law enforcement officers, and rescue, recovery, and cleanup workers who responded to the September 11, 2001, terrorist attacks in New York City, at the Pentagon, and in Shanksville, Pennsylvania (responders), and to eligible persons who were present in the dust or dust cloud on September 11, 2001 or who worked, resided, or attended school, childcare, or adult daycare in the New York City disaster area (survivors). Certain specific activities of the WTC Program Administrator are reserved to the Secretary, HHS, to delegate at her discretion; other WTC Program Administrator duties not explicitly reserved to the Secretary, HHS, are assigned to the Director, NIOSH. The administration of the Advisory Committee is left to the Director of NIOSH in his role as WTC Program Administrator. CDC and NIOSH provide funding, staffing, and administrative support services for the Advisory Committee. The charter was reissued on May 12, 2015, and will expire on May 12, 2017.
Matters for Discussion: The Advisory Committee will address the new responsibilities required under the reauthorization of the WTC Health Program in the PHS Act. Specifically, the enhanced role of the STAC to: (1) Make recommendations regarding the identification of individuals to conduct independent peer reviews of the evidence that would be the basis for issuing final rules to add a health condition to the List of WTC-Related Health Conditions; and (2) review and evaluate the policies and procedures in effect within the WTC Health Program that are used to determine whether sufficient evidence is available to support adding a non-cancer condition or type of cancer to the List of WTC-Related Health Conditions.
The two policies can be found at: http://www.cdc.gov/wtc/policies.html.
The agenda will include workgroup presentations on independent peer review and the policies and procedures the WTC Health Program uses to add health conditions to the list of covered conditions.
The agenda is subject to change as priorities dictate.
To view the notice, visit http://www.regulations.gov and enter CDC-2016-0093 in the search field and click “Search.”
Public Comment Sign-up and Submissions to the Docket: To sign up to provide public comments or to submit comments to the docket, send information to the NIOSH Docket Office by one of the following means:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS C-34, 1090 Tusculum Avenue, Cincinnati, Ohio 45226.
Telephone: (513) 533-8611.
In the event an individual cannot attend, written comments may be submitted. The comments should be limited to two pages and submitted through http://www.regulations.gov by October 31, 2016. Efforts will be made to provide the two-page written comments received by the deadline above to the committee members before the meeting. Comments in excess of two pages will be made publicly available at http://www.regulations.gov.
Policy on Redaction of Committee Meeting Transcripts (Public Comment): Transcripts will be prepared and posted to http://www.regulations.gov within 60 days after the meeting. If a person making a comment gives his or her name, no attempt will be made to redact that name. NIOSH will take reasonable steps to ensure that individuals making public comments are aware of the fact that their comments (including their name, if provided) will appear in a transcript of the meeting posted on a public Web site. Such reasonable steps include a statement read at the start of the meeting stating that transcripts will be posted and names of speakers will not be redacted. If individuals in making a statement reveal personal information (e.g., medical information) about themselves, that information will not usually be redacted. The CDC Freedom of Information Act coordinator will, however, review such revelations Start Printed Page 71505in accordance with the Freedom of Information Act and, if deemed appropriate, will redact such information. Disclosures of information concerning third party medical information will be redacted.
Contact person for more information: Paul J. Middendorf, Ph.D., Designated Federal Officer, NIOSH, CDC, 2400 Century Parkway NE., Mail Stop E-20, Atlanta, Georgia 30345, telephone 1 (888) 982-4748; email: email@example.com.
The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.Start Signature
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 2016-25039 Filed 10-14-16; 8:45 am]
BILLING CODE 4163-18-P